Indication
Non-Hodgkin lymphoma
181 clinical trials
227 products
35 drugs
2 abstracts
Product
JCAR017Clinical trial
A Multicenter, Non-interventional, Observational, Prospective Study to Assess Hypotension in Patients With Primary Immunodeficiency Disease Treated With Bivigam™ (Human 10%) or Other Commercial Human 10% Immune Globulin (Intravenous) (IGIV) Products During Infusion and up to 72 Hours Post InfusionStatus: Active (not recruiting), Estimated PCD: 2022-12-31
Product
VenetoclaxProduct
STK-009Clinical trial
A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2026-06-24
Product
CyclophosphamideProduct
SYNCAR-001Product
FludarabineClinical trial
A Phase 2/3, Randomized, Double Blind, Placebo-controlled, Multicenter Study of NKTR-255 vs Placebo Following CD19-directed CAR-T Cell Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaStatus: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase Ib, Multi-center, Open-label Dose Escalation and Expansion Platform Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (NHL)Status: Recruiting, Estimated PCD: 2026-10-30
Product
VAY736Product
lenalidomideClinical trial
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2021-09-02
Product
pembrolizumabClinical trial
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2022-09-13
Product
NKTR-255Product
ChemotherapyProduct
blinatumomabClinical trial
A Phase Ia/Ib Dose-escalation and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SCTB35 in Patients With CD20+ Relapse/Refractory B-cell Non-Hodgkin LymphomaStatus: Not yet recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase Ib/II Study of APG-1252 as a Single Agent or in Combination With Other Therapeutic Agent in Patients With Relapsed and/or Refractory Non-Hodgkin Lymphoma(NHL)Status: Recruiting, Estimated PCD: 2025-09-01
Product
ChidamideProduct
APG-1252Clinical trial
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's LymphomasStatus: Active (not recruiting), Estimated PCD: 2024-02-01
Product
SCTB35Product
CG-806Clinical trial
A Multicenter, Open Phase I Study to Evaluate the Safety and Pharmacokinetic Profile of F01 in Patients With Relapsed/Refractory Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2025-01-01
Product
F01Product
CDX-1140Product
CDX-301Clinical trial
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2024-06-30
Product
CNCT19Product
WTX-330Clinical trial
A Phase 1 (First-In-Human [FIH]), Multi-Site, Dose Escalation and Expansion Study of WTX-330 in Adult Patients With Advanced or Metastatic Solid Tumors or LymphomaStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2023-07-19
Product
TiragolumabProduct
MosunetuzumabProduct
AtezolizumabProduct
CC-122Clinical trial
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating CC-122Status: Active (not recruiting), Estimated PCD: 2026-02-25
Product
DexamethasoneClinical trial
AN OPEN-LABEL, PHASE 1 STUDY EVALUATING THE PHARMACOKINETICS, SAFETY AND ANTI-TUMOR ACTIVITY OF PF-07901801 (TTI-622) MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED HEMATOLOGIC MALIGNANCIESStatus: Recruiting, Estimated PCD: 2025-02-26
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell MalignanciesStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)Status: Active (not recruiting), Estimated PCD: 2026-07-01
Product
CTX110Product
AS-1763Clinical trial
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialStatus: Active (not recruiting), Estimated PCD: 2025-05-27
Product
MaplirpaceptClinical trial
A Phase 1b Study of Oral AS-1763 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2027-09-01
Product
BGB-16673Clinical trial
Phase 1, First-in-human, Open-label Dose Escalation and Cohort Expansion Study of KB-0742 in Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2025-12-01
Product
KB-0742Product
GlofitamabProduct
ObinutuzumabProduct
TocilizumabClinical trial
A Multicenter, Open-Label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-Treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2025-08-28
Product
ATG-019Product
ATG-019 + Niacin ERClinical trial
A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3Status: Active (not recruiting), Estimated PCD: 2020-08-31
Product
PlaceboProduct
CopanlisibProduct
RituximabClinical trial
A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaStatus: Terminated, Estimated PCD: 2023-10-02
Product
MB-CART20.1Clinical trial
A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART20.1 in Patients With Relapsed or Resistant CD20 Positive B-NHLStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
An Open, Multicenter, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacokinetics, and Antitumor Activity of GNC-038 Injection in Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHLStatus: Recruiting, Estimated PCD: 2025-02-01
Product
GNC-038Clinical trial
A Phase 1, First-In-Human, Open-Label, Dose-Escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Intravenous Doses of BITR2101 (Anti-TNFR2) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Including Cutaneous and Peripheral T Cell LymphomaStatus: Not yet recruiting, Estimated PCD: 2027-02-01
Product
BITR2101Clinical trial
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell MalignanciesStatus: Recruiting, Estimated PCD: 2027-06-27
Product
mRNA-2752Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint BlockadeStatus: Active (not recruiting), Estimated PCD: 2024-05-15
Product
DurvalumabProduct
ABBV-525Product
GLB-002Clinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)Status: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2025-05-30
Product
Polatuzumab vedotinProduct
OxaliplatinClinical trial
A Phase 1b/2 Study of Tafasitamab, Tafasitamab Plus Lenalidomide, Tafasitamab Plus Parsaclisib, and Tafasitamab Plus Lenalidomide in Combination With R-CHOP in Japanese Participants With Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2025-05-31
Product
R-CHOPProduct
GemcitabineClinical trial
A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell MalignanciesStatus: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Phase Ib Study Evaluating Glofitamab (RO7082859) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin (POLA) Plus Rituximab (R), Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) or in Participants With Untreated Diffuse Large B-Cell Lymphoma (DLBCL)Status: Active (not recruiting), Estimated PCD: 2024-10-30
Product
DoxorubicinProduct
VincristineProduct
tafasitamabProduct
parsaclisibProduct
PrednisoneClinical trial
A Phase I Clinical Study of Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ETH-155008 Tablets in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2025-12-01
Product
ETH-155008Product
Lisocabtagene maraleucelProduct
Idecabtagene vicleucelProduct
GEN3017Clinical trial
A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2029-12-31
Product
EpcoritamabClinical trial
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2032-11-26
Product
CC-99282Product
LenalidomideProduct
IbrutinibProduct
Doxorubicin HydrochlorideProduct
Polatuzumab VedotinClinical trial
A Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity, and Clinical Benefit of a CMV Immunotherapeutic Vaccine in Donors and CMV-Seropositive Recipients Undergoing Allogeneic, Matched Hematopoietic Cell Transplant (HCT)Status: Completed, Estimated PCD: 2009-11-30
Product
VCL-CB01Product
CHO-H01Clinical trial
A Phase I/IIa, Open-label, Multicenter Study of the Safety and Efficacy of CHO-H01 as a Single Agent to Subjects With Refractory or Relapsed Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL [APOLLO])Status: Recruiting, Estimated PCD: 2028-02-28
Product
TR115Clinical trial
A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)Status: Completed, Estimated PCD: 2022-05-10
Clinical trial
An Open-label, First-in-human, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and LymphomasStatus: Completed, Estimated PCD: 2022-12-02
Clinical trial
A Phase I Dose Escalation Study of ZN-d5 Monotherapy in Chinese Subjects With Non-Hodgkin LymphomaStatus: Terminated, Estimated PCD: 2023-05-26
Clinical trial
A Phase Ⅰ Study of ADG106 Administered in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2021-11-01
Product
ZN-d5Clinical trial
Open-label, Uncontrolled, Single-arm, Phase Ib/II Study of Intravenous Copanlisib in Japanese Patients With Indolent B-cell Non Hodgkin's Lymphomas Relapsed After or Refractory to Standard TherapyStatus: Completed, Estimated PCD: 2018-09-14
Clinical trial
A Modular Phase I/II, Open-label, Dose Escalation and Expansion, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Patients With Advanced Non-Hodgkin Lymphoma.Status: Terminated, Estimated PCD: 2023-08-17
Product
ADG106Product
AZD0466Clinical trial
A Phase Ib/II Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With B-Cell Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2018-12-19
Product
PrednisoloneProduct
ElimusertibClinical trial
A Phase 1, Open-label, Multi-center, Dose Escalation and Dose Expansion Study of NKTR-255 in Relapsed or Refractory Hematological MalignanciesStatus: Completed, Estimated PCD: 2023-04-24
Clinical trial
A Phase 1a/1b Dose Escalation and Dose Expansion, First-in-human, Open-Labeled Study of ETH-155008 in Subjects With Relapsed or Refractory B-cell NHL, CLL/SLL and AMLStatus: Terminated, Estimated PCD: 2023-05-02
Product
Daratumumab/rHuPH20Clinical trial
A Phase Ia/Ib Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma, and as a Single Agent and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaStatus: Terminated, Estimated PCD: 2023-03-28
Product
DaratumumabProduct
BAT4306FClinical trial
A Phase I Clinical Trial of BAT4306F (for Injection) on Safety, Tolerability and Pharmacokinetics for Patients With CD20-positive, B-cell Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2021-01-13
Product
MT-601Product
rituximabClinical trial
A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Rituximab in Subjects With CD20-positive Lymphoid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-05-03
Clinical trial
A Study of CD137 Agonist ADG106 Administered Intravenously in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2022-01-24
Clinical trial
A Multicenter, Open-label, Phase 1 Study Evaluating the Safety and Tolerability of HMPL-760 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Other Non-Hodgkin Lymphoma (NHL)Status: Withdrawn, Estimated PCD: 2022-11-16
Clinical trial
An Open-Label Study to Evaluate Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab TreatmentStatus: Completed, Estimated PCD: 2015-06-18
Product
BendamustineProduct
HMPL-760Clinical trial
A Phase I Study to Evaluate the Safety and Immunogenicity of 3D189 in Patients With Hematologic MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Product
BN102Product
3D189Clinical trial
A Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN102 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin's Lymphoma (NHL)Status: Withdrawn, Estimated PCD: 2024-07-30
Clinical trial
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's LymphomaStatus: Terminated, Estimated PCD: 2021-02-01
Product
KPT-9274Product
Niacin ERProduct
NivolumabClinical trial
Allogeneic Natural Killer T-Cells Expressing CD19 Specific Chimeric Antigen Receptor and Interleukin-15 in Relapsed or Refractory B-Cell Malignancies 2Status: Recruiting, Estimated PCD: 2023-12-01
Product
ABT-263Product
KUR-502Clinical trial
First-in-Human Dose Study of IOA-244 Alone and in Combination With Pemetrexed/Cisplatin in Patients With Advanced or Metastatic CancersStatus: Active (not recruiting), Estimated PCD: 2023-09-01
Product
AvelumabProduct
CisplatinProduct
IOA-244Product
PemetrexedProduct
RuxolitinibProduct
CTX112Clinical trial
A Phase I/Ⅱ Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of MBS303 in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2024-11-01
Product
CC-97540Product
MBS303Clinical trial
A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell MalignanciesStatus: Recruiting, Estimated PCD: 2030-01-01
Clinical trial
A Phase 1, Multicenter, Open-label Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-06-21
Clinical trial
A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression (CheckMate 436: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 436)Status: Completed, Estimated PCD: 2020-01-16
Product
Brentuximab VedotinClinical trial
A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Venetoclax in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Polatuzumab Vedotin and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaStatus: Completed, Estimated PCD: 2022-08-04
Product
MOR00208Clinical trial
A Phase IIa, Open-label, Multicenter Study of Single-agent MOR00208, an Fc-optimized Anti-CD19 Antibody, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2022-04-06
Product
PBCAR0191Clinical trial
Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)Status: Recruiting, Estimated PCD: 2024-03-01
Product
GentulizumabProduct
IpilimumabProduct
LirilumabProduct
PomalidomideClinical trial
Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic MalignanciesStatus: Active (not recruiting), Estimated PCD: 2020-09-25
Clinical trial
A Phase Ia, Open-label, Dose Escalation Study of Safety, Tolerability, Pharmacokinetics of Gentulizumab, an Anti-CD47 Monoclonal Antibody, in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma (NHL)Status: Terminated, Estimated PCD: 2023-05-30
Product
chemotherapyProduct
venetoclaxClinical trial
An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy (ELM-1)Status: Active (not recruiting), Estimated PCD: 2025-12-02
Clinical trial
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory MalignanciesStatus: Completed, Estimated PCD: 2023-04-19
Product
OdronextamabClinical trial
A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Imvotamab (IGM-2323) as a Single Agent and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin LymphomasStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Product
imvotamabClinical trial
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological MalignanciesStatus: Terminated, Estimated PCD: 2019-07-25
Product
AMG 397Product
AzacitidineClinical trial
LMY-920 for Treatment of Relapsed or Refractory Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2025-05-01
Product
BAFF CAR-TClinical trial
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell MalignanciesStatus: Active (not recruiting), Estimated PCD: 2019-04-03
Product
CD22-CARClinical trial
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot StudyStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
IPUH71Clinical trial
Canadian-Led Immunotherapies in Cancer: CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2024-10-01
Product
CLIC-1901Clinical trial
Administration of Rapidly Generated EBV-Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive LymphomaStatus: Recruiting, Estimated PCD: 2024-12-01
Product
EBV-specific T cellsClinical trial
An Open-Label, Pilot Study of Romiplostim for Conditioning Regimen-Related Thrombocytopenia After High-Dose Therapy and Autologous Hematopoietic Cell TransplantationStatus: Completed, Estimated PCD: 2023-06-08
Product
RomiplostimClinical trial
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive LymphomasStatus: Not yet recruiting, Estimated PCD: 2028-07-01
Product
C7R.CD30.CAR-EBVST cellsClinical trial
A Pilot Study of Subcutaneous Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for Untreated Indolent B-Cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
CLIC-02: A Phase I Trial of CLIC-2201 for the Treatment of Relapsed/Refractory B Cell MalignanciesStatus: Not yet recruiting, Estimated PCD: 2026-08-01
Product
CLIC-2201Clinical trial
Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasStatus: Recruiting, Estimated PCD: 2028-06-01
Drug
VincristineProduct
EtoposideDrug
PomalidomideDrug
cyclophosphamideDrug
VarlilumabClinical trial
Autologous Stem Cell Transplant In Patients With Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)Status: Recruiting, Estimated PCD: 2025-09-30
Product
BCNUProduct
AraCDrug
MelphalanDrug
FilgrastimClinical trial
Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell LymphomasStatus: Completed, Estimated PCD: 2022-10-22
Product
PembrolizumabClinical trial
Randomized Phase 2 Trial of Isatuximab During Autologous Stem Cell Collection and Transplantation Period in Patients With Multiple Myeloma, Relapsed Hodgkin's and Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2025-03-01
Product
IsatuximabClinical trial
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaStatus: Recruiting, Estimated PCD: 2024-07-15
Drug
obinutuzumabDrug
prednisoneDrug
lenalidomideProduct
PolatuzumabDrug
ibrutinibDrug
venetoclaxClinical trial
A Phase I/II Study of Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) (BMS Protocol 180129)Status: Completed, Estimated PCD: 2016-08-01
Product
DasatinibClinical trial
Phase I/II Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2016-10-25
Product
ofatumumabClinical trial
Phase I Study of Activated T Lymphocytes Expressing Chimeric Antigen Receptors for Therapy of Relapsed CD19-Positive Malignancies Post-Allogeneic Hematopoietic Stem Cell Transplantation Infused Only After Engraftment (CARPASCIO)Status: Active (not recruiting), Estimated PCD: 2019-10-01
Product
CD19.CAR-CD28Z T CellsClinical trial
In Situ Vaccination With Flt3L, Radiation, and Poly-ICLC Combined With Pembrolizumab in Patients With Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-03-01
Product
Flt3LProduct
Poly ICLCClinical trial
Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL)Status: Recruiting, Estimated PCD: 2025-02-24
Product
TAA-specific CTLsClinical trial
A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationStatus: Active (not recruiting), Estimated PCD: 2024-06-17
Product
ItacitinibClinical trial
Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and EngraftmentStatus: Completed, Estimated PCD: 2022-09-20
Product
Anti-Thymocyte GlobulinClinical trial
A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Hematopoietic Stem Cells From HLA-compatible Related or Unrelated Donors in Patients With B-Cell Lymphoid MalignanciesStatus: Withdrawn, Estimated PCD: 2026-03-01
Product
Hematopoietic Stem CellsClinical trial
A Phase 2 Study of Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular LymphomaStatus: Active (not recruiting), Estimated PCD: 2027-01-01
Clinical trial
TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-01
Product
ZoledronateClinical trial
Phase I Study of the Administration of EBV CTLs Expressing CD30 Chimeric Receptors for Relapsed CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma (CAR CD 30)Status: Active (not recruiting), Estimated PCD: 2012-05-29
Product
CAR.CD30 EBV specific-CTLsClinical trial
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant NeoplasmStatus: Active (not recruiting), Estimated PCD: 2023-10-04
Product
Antiretroviral TherapyClinical trial
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study of CLN-978 in Patients With Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL)Status: Active (not recruiting), Estimated PCD: 2026-11-01
Product
CLN-978Clinical trial
Phase I Study of Activated T-Cells Expressing Second or Third Generation CD19-Specific Chimeric Antigen Receptors for Advanced B-Cell Non-Hodgkin's Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia (SAGAN)Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaStatus: Recruiting, Estimated PCD: 2024-06-01
Product
RevlimidClinical trial
A Phase I Study Of Split-Course Bridging Radiotherapy (SC-BRT) Prior To Commercial CD19 CAR T-Cell Therapies For Patients With Relapsed or Refractory B-Cell LymphomasStatus: Recruiting, Estimated PCD: 2025-10-01
Product
Conditioning chemotherapyProduct
CAR T-cellClinical trial
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological DiseasesStatus: Recruiting, Estimated PCD: 2024-10-01
Product
Cyclosporine AProduct
Mycophenylate mofetilProduct
Umbilical cord bloodClinical trial
Safety and Feasibility of On-Site Manufacture of CD19 CAR T Cells Using the CliniMACS Prodigy in Pediatric and Young Adult Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia and Non-Hodgkin's LymphomaStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Phase II, Single Arm, Open Label Multi-center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent Non-Hodgkin's LymphomasStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell LymphomasStatus: Completed, Estimated PCD: 2018-08-27
Product
OfatumumabProduct
CarboplatinClinical trial
Tacrolimus, Mini-dose Methotrexate and Mycophenolate Mofetil Versus Tacrolimus and Methotrexate for the Prevention of Acute Graft-versus-Host-DiseaseStatus: Completed, Estimated PCD: 2020-10-09
Drug
tacrolimusClinical trial
Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line TherapyStatus: Completed, Estimated PCD: 2021-05-03
Clinical trial
A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-01-18
Drug
AtezolizumabClinical trial
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of CMV-MVA Triplex Vaccine in Adult Recipients of Haploidentical Hematopoietic Stem Cell TransplantStatus: Active (not recruiting), Estimated PCD: 2030-04-07
Product
LetermovirClinical trial
Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-modified Autologous T Cells (CART19) in Patients With Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma. A Dose Escalation, Open-label, Phase I Study.Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
CD19/CD20/BCMA CAR T cellsClinical trial
Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant DisordersStatus: Recruiting, Estimated PCD: 2025-12-20
Product
ClofarabineClinical trial
Prospective Randomized Multicenter Study in First-line Treatment of Advanced progredIeNT Follicular And Other IndoleNt and Mantle Cell LymphomasStatus: Active (not recruiting), Estimated PCD: 2030-04-01
Clinical trial
A Phase Ib/IIa Study of Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and MyelomaStatus: Completed, Estimated PCD: 2023-10-01
Product
RomidepsinClinical trial
A Phase 1 Study Evaluating SC262, a Hypoimmune, Allogeneic CD22-directed CAR T Cell Therapy, in Relapsed and/or Refractory Non-Hodgkin's Lymphoma (VIVID)Status: Recruiting, Estimated PCD: 2028-03-01
Product
SC262Drug
fludarabineProduct
BusulfanProduct
Cyclosporine-AProduct
Mycophenolate MofetilProduct
Cord Blood GraftClinical trial
Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid MalignanciesStatus: Recruiting, Estimated PCD: 2025-03-10
Product
VIP152Clinical trial
Opioid-Sparing Pain Treatment In Myeloma And Lymphoma Patients Undergoing High-Dose Chemotherapy (OPTIMAL-HiChemo): Randomized Controlled TrialStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Product
opioidClinical trial
Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHLStatus: Recruiting, Estimated PCD: 2024-12-01
Product
Liposomal ARA-CProduct
IfosfamideDrug
AN0025Clinical trial
A Phase 1/2 Single-center Study Evaluating the Safety and Efficacy of TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell (ATHENA) Therapy in Adults With Refractory/Relapsed B-cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Phase II Study of Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non Hodgkin's LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell TransplantationStatus: Recruiting, Estimated PCD: 2025-12-01
Product
Cytokine-treated Veto CellsClinical trial
Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in Patients Ineligible for HCT-ASCT With Primary Central Nervous System Lymphoma (PCNSL)Status: Not yet recruiting, Estimated PCD: 2027-02-01
Drug
TafasitamabDrug
DocetaxelClinical trial
Allogenic CD19-targeting Chimeric Antigen Receptor γδT Cells Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2025-12-31
Product
Allogenic CD19-CAR-γδT cellDrug
methotrexateProduct
Mycophenolate mofetilClinical trial
Once Daily Intravenous Busulfex as Part of Reduced-toxicity Conditioning for Patients With Relapsed/Refractory Hodgkin's and Non-Hodgkin's Lymphomas Undergoing Allogeneic Hematopoietic Progenitor Cell Transplantation - A Multicenter Phase II StudyStatus: Completed, Estimated PCD: 2021-09-27
Product
MethotrexateClinical trial
A Phase I Study Evaluating Copanlisib in Combination With R-GCD (Gemcitabine, Carboplatin, Dexamethasone, and Rituximab) With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and High-Risk Follicular LymphomaStatus: Terminated, Estimated PCD: 2022-04-27
Drug
pegfilgrastimClinical trial
Pilot Safety-feasibility Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to EpcoritamabStatus: Not yet recruiting, Estimated PCD: 2028-09-01
Product
SiltuximabDrug
EpcoritamabClinical trial
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological MalignanciesStatus: Terminated, Estimated PCD: 2022-11-11
Product
ThiotepaProduct
DilanubicelClinical trial
CMV-MVA Triplex Vaccination of Stem Cell Donors to Enhance CMV Specific Immunity and Prevent CMV Viremia in Recipients After Stem Cell TransplantStatus: Active (not recruiting), Estimated PCD: 2022-01-22
Clinical trial
A Phase I/Ib Study of Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide and/or BendamustineStatus: Active (not recruiting), Estimated PCD: 2025-08-25
Clinical trial
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersStatus: Recruiting, Estimated PCD: 2025-12-30
Product
IDP-023Clinical trial
CASPALLO: A Phase I Study Evaluating the Use of Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell TransplantationStatus: Active (not recruiting), Estimated PCD: 2011-11-01
Product
Allodepleted T CellsDrug
R-CHOPDrug
IL-2Clinical trial
An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell MalignanciesStatus: Recruiting, Estimated PCD: 2028-07-31
Drug
TocilizumabClinical trial
A Phase II Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2020-01-27
Product
BlinatumomabClinical trial
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell TransplantationStatus: Completed, Estimated PCD: 2024-03-08
Clinical trial
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological MalignanciesStatus: Completed, Estimated PCD: 2016-08-01
Drug
PlerixaforClinical trial
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell TransplantStatus: Active (not recruiting), Estimated PCD: 2018-03-04
Product
CMVpp65-A*0201Clinical trial
A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity ConditioningStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase Ib, Open Label Study to Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-CelStatus: Recruiting, Estimated PCD: 2038-04-01
Product
Axicabtagene CiloleucelClinical trial
Phase I Study of the Administration of Multi-Virus-Specific Cytotoxic T Lymphocytes Expressing CD19 Chimeric Receptors for Prophylaxis or Therapy of Relapse of CD19 Positive Malignancies Post Hematopoietic Stem Cell TransplantationStatus: Active (not recruiting), Estimated PCD: 2016-04-01
Product
BenadrylClinical trial
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32]Status: Completed, Estimated PCD: 2023-04-17
Drug
AllopurinolProduct
ATGProduct
Peripheral Blood Stem CellsProduct
Bone Marrow CellsClinical trial
Post-Transplant Use of Irradiated Haplo-Allogeneic CellsStatus: Terminated, Estimated PCD: 2022-06-30
Product
Irradiated Allogeneic CellsClinical trial
LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins LymphomaStatus: Completed, Estimated PCD: 2008-12-01
Product
LSA4Clinical trial
A Phase I/II Multicenter Study Evaluating the Safety and Efficacy of Allogeneic GDA-201 Natural Killer Cells in Patients With Relapsed/Refractory B Cell Non-Hodgkin LymphomaStatus: Terminated, Estimated PCD: 2024-04-22
Product
GDA-201Clinical trial
Phase I Clinical Trial Evaluating the Safety and Efficacy of Point-of-care CAR-T-cell Therapy in the Treatment of Relapsed/Refractory CD19+ Non-Hodgkin Lymphoma and Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2025-07-31
Product
anti-CD19 CAR T-cellsClinical trial
Long-term Follow-up and/or Continued Thalidomide (THALOMID®) Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165Status: Completed, Estimated PCD: 2023-08-02
Product
ThalidomideClinical trial
T Cells Expressing a Fully-Human Anti-CD19 Chimeric Antigen Receptor for Treating B-cell MalignanciesStatus: Completed, Estimated PCD: 2018-06-12
Clinical trial
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ LymphomasStatus: Completed, Estimated PCD: 2019-09-16
Drug
TisagenlecleucelClinical trial
A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2025-04-01
Product
CarmustineDrug
TQB2450Product
CytarabineProduct
19-28z T CELLSClinical trial
Phase II Study of Palifermin With Leuprolide Acetate or Degarelix For the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantationStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
PaliferminDrug
LHRH agonistProduct
DegarelixClinical trial
A Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesStatus: Completed, Estimated PCD: 2018-04-12
Drug
MotixafortideClinical trial
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor for Relapsed CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma (CART CD30)Status: Withdrawn, Estimated PCD: 2016-01-28
Product
CAR.CD30 T cellsClinical trial
A Randomized Phase II Study Evaluating the Efficacy of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell TransplantationStatus: Recruiting, Estimated PCD: 2025-04-01
Product
Hyperbaric oxygenClinical trial
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the Oral BCL-2 Inhibitor LP-108 in Patients With Relapsed or Refractory B-cell LymphomaStatus: Recruiting, Estimated PCD: 2023-12-01
Product
LP-108Clinical trial
Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active or Relapsed Hodgkin or Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2021-09-27
Product
Antigen-EscalationProduct
Dose-EscalationProduct
Pediatric multiTAA T cellsClinical trial
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma：a Single-center, Open-label, Phase II Clinical Trial.（REPLY Study）Status: Recruiting, Estimated PCD: 2023-12-31
Product
IBI376Clinical trial
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Patients With B-Cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2026-07-15
Product
CC-220Drug
golcadomideDrug
Vitamin D3Clinical trial
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of an Allogeneic Hematopoietic Stem Cell TransplantStatus: Active (not recruiting), Estimated PCD: 2018-01-25
Clinical trial
A Phase I Study of Recombinant Human Interleukin-18 (SB-485232) in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for LymphomaStatus: Completed, Estimated PCD: 2016-03-01
Clinical trial
FATE FT596 With Rituximab as Relapse Prevention in High Risk Patients After Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-02-08
Product
FT596Clinical trial
An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2025-11-15
Product
BTCT4465AClinical trial
An Investigator-Sponsored Phase Ib Trial of Venetoclax and SINE: Selective Inhibition of Nuclear Export in Patients With High Risk Hematologic MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Drug
SelinexorClinical trial
A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive ChemotherapyStatus: Terminated, Estimated PCD: 2021-09-01
Product
GenisteinClinical trial
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-06-30
Product
IrinotecanProduct
VeliparibClinical trial
Phase I Study Of The Administration Of Peripheral Activated T-Cells and EBV Specific CTLs Expressing CD19 Chimeric Receptors For Advanced B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia (ATECRAB)Status: Active (not recruiting), Estimated PCD: 2012-05-01
Clinical trial
A Phase 2 Study of Acalabrutinib With DA-EPOCH-R or R-CHOP for Patients With Untreated Diffuse Large B-cell LymphomaStatus: Recruiting, Estimated PCD: 2025-05-31
Product
DA-EPOCHProduct
CHOPClinical trial
Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic MalignanciesStatus: Completed, Estimated PCD: 2019-11-05
Clinical trial
Phase I Study of Relapsed CD30 Expressing Lymphoma Treated With CD30 CAR T Cells (RELY-30)Status: Recruiting, Estimated PCD: 2026-04-01
Product
CAR T CellsClinical trial
An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell TherapyStatus: , Estimated PCD: 2041-12-01
Product
Allogeneic CAR-TClinical trial
Phase II Trial of Hihg-Dose Thiotepa, Busulfan, Cyclophosphamide, and Rituximab With Autologous Stem Cell Transplantation for Patients With CNS Involvement by Non-Hodgkin's Lymphoma or Primary CNS LymphomaStatus: Completed, Estimated PCD: 2015-12-01
Product
High-dose chemotherapyClinical trial
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in AdultsStatus: Recruiting, Estimated PCD: 2028-05-22
Product
Conditioning ChemotherapyProduct
Cord blood graftClinical trial
Phase I Study of Cytokine Release Syndrome Prophylaxis and Treatment With SiltuximabStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Placebo-Controlled and Randomized Phase 2 Trial of CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients After Hematopoietic Stem Cell TransplantStatus: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
Phase 1/1b Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Adolescent and Adult Patients With Relapsed and/or Refractory B-Non-Hodgkin's Lymphoma (B-NHL)Status: Recruiting, Estimated PCD: 2024-12-01
Product
CD19x22 CAR T CellsClinical trial
A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation With Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell TransplantationStatus: Active (not recruiting), Estimated PCD: 2023-08-21
Product
MelphalanDrug
sirolimusDrug
GemcitabineProduct
IGM-2323Product
ImvotamabProduct
Loncastuximab TesirineClinical trial
A Phase 1/2 Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma.Status: Completed, Estimated PCD: 2022-10-25
Product
BetalutinProduct
LilotomabProduct
100 mg/m2 LilotomabClinical trial
An Open-Label, Single-Arm Study of Relma-cel, CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for Relapsed or Refractory (R/R) LBCLStatus: Not yet recruiting, Estimated PCD: 2025-04-30
Product
Relma-celClinical trial
An Open-label, Multicenter, Phase I Safety Study of AXT-1003 in Subjects With Advanced Malignant TumorsStatus: Not yet recruiting, Estimated PCD: 2027-03-01
Product
AXT-1003Clinical trial
A Single-arm, Multi-center, Prospective Clinical Study of Mitoxantrone Hydrochloride Liposome Injection-based CMOP±R Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's LymphomaStatus: Not yet recruiting, Estimated PCD: 2025-08-31
Product
CMOP±R